Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.58 |
| ▸ | ITGAV | P06756 | 1/20 | 0.58 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | PPARG | P37231 | 8/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.52 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6247819 | 1.00 | ACE (0.60) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL14250272 | 1.00 | ACE (0.60) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL27341117 | 0.90 | ACE (0.58) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL7394806 | 0.90 | ACE (0.58) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL7296608 | 0.90 | ACE (0.58) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL7394803 | 0.90 | ACE (0.58) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL7388523 | 0.89 | ACE (0.62) | ACEITGB3ITGA2BITGB1ITGAV | |
| SCHEMBL7388520 | 0.89 | ACE (0.62) | ACEITGB3ITGA2BITGB1ITGAV | |
| Iodide SCHEMBL7301004 | 0.89 | ACE (0.57) | ACEITGB3ITGA2BITGB1ITGAV | |
| Hydrochloric Acid SCHEMBL5671540 | 0.89 | ACE (0.57) | ACEITGB3ITGA2BITGB1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | UAB RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
| WO-2020033317-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2020-02-13 | — | — | WO | disclosed |
| CN-103582644-B | Phthalazinone-Pyrrolopyrimidine Carboxamide Derivatives | 塔科达有限责任公司 | 2016-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | TGFBR2, SMAD2, TGFB2 | ACE 2029/4885ITGB3 272/4885ITGA2B 509/4885 |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | TGFBR2, SMAD2, TGFB2 | ACE 2029/4885ITGB3 272/4885ITGA2B 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.